Immunotherapy is a treatment procedure which enhances or supress the body’s immune system to fight against a disease. Immunotherapies which enhance the immune response are called as activation immunotherapies and those which reduce or suppress the immune response are called as suppression immunotherapies. Immunotherapy is of many types but the major immunotherapies for cancer include Monoclonal antibodies, Cancer vaccines and Non-specific immunotherapies.

Severe SARS-CoV2, the latest pandemic infectious diseases, is a serious threat to human health. SARSCoV2 infection causes immune activation and systemic hyper-inflammation which can lead to respiratory distress syndrome (ARDS). ARDS victims are linked to sustained IL-6 and IL-1 increase. Macrophage activation associated with the “cytokine storm” promote the dysregulation of the innate immunity. So far without vaccines or specific therapy, all efforts to design drugs or clinical trials are deserving. Vitamin D and its receptor vitamin D receptor (VDR) exert an important role in infections for their remarkable impact on both innate and adaptive immune responses and on the suppression of inflammatory process. The protective effects of vitamin D supplementation have been proved by several observational studies and by meta-analysis of clinical trials for prevention of viral acute respiratory infection. In this review we compare the mechanisms of host immune response to SARS-CoV2 infection and the immunomodulatory actions that vitamin D exert in order to explore the preventive effect of vitamin D supplementation on SARS-CoV2 viral infection. For more information kindly visit https://www.longdom.org/open-access/exploring-the-immunomodulatory-effects-of-vitamin-d3-in-sarscov2-management.pdf

Kindly submit your manuscript at https://www.longdom.org/submissions/immunotherapy-open-access.html or you can mail through this mail id as an attachments immunother@emedsci.com 

Explore more information at Immunotherapy Open Access. You can share your experiences too by publishing your novel fact findings in this Journal.

Regards

Alex John
Immunotherapy Open Access
Editorial Manager     
E-mail id: immunotherapy@scholarlymed.com